Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1987 Feb;90(2):335–345. doi: 10.1111/j.1476-5381.1987.tb08963.x

N-propargylbenzylamine, a major metabolite of pargyline, is a potent inhibitor of monoamine oxidase type B in rats in vivo: a comparison with deprenyl.

F Karoum
PMCID: PMC1916954  PMID: 3103805

Abstract

In an effort to explore the contribution of the metabolites of pargyline towards the in vivo inhibition of monoamine oxidase (MAO), the effects of pargyline and its major metabolites on the production and metabolism of a number of biogenic amines were studied in rats. The administration of pargyline gave rise to three major ethyl acetate extractable metabolites: benzylamine, N-methylbenzylamine and N-propargylbenzylamine (NPB). Only NPB demonstrated in vivo monoamine oxidase inhibitory properties at an acute dose of 30 mg kg-1. The acute effects of pargyline, NPB, and deprenyl on urine and brain concentrations of a number of biogenic amines (phenylethylamine (PEA), m- and p-tyramine, noradrenaline (NA), dopamine, and 5-hydroxytryptamine (5-HT) and their metabolites were evaluated. Increased urine and brain concentrations of PEA were considered to represent in vivo inhibition of type B MAO while decreased concentrations of NA and 5-HT metabolites were regarded as indicators of an in vivo inhibition of MAO type A. NPB, like deprenyl and pargyline, significantly increased urine and brain PEA while only pargyline reduced 5-HT metabolism, suggesting that the metabolism of pargyline to NPB may contribute towards the MAO type B inhibitory effects of pargyline in vivo. Since the therapeutic benefits of MAO inhibitors in clinical practice usually require some period of chronic treatment, the chronic effects of repeated 14 daily doses of the above MAO inhibitors on central and peripheral biogenic amines were evaluated at the following times: during treatment, one day and five days after termination of treatment. The biochemical changes observed during the course of chronic NPB, pargyline and deprenyl treatments generally follow the expected in vitro characteristics of these drugs, but the detailed changes observed suggest clear differences. For example, the in vivo effect of pargyline on urine 5-hydroxyindoleacetic acid excretion was considerably weaker than its effect on the excretion of NA and dopamine metabolites. These changes are opposite to the in vitro effects of pargyline on 5-HT, dopamine and NA oxidative deamination. Inhibitions of the metabolism of all the amines studied were clearly observed during chronic MAOI treatments, but these effects were less evident five days after the end of treatment, suggesting an almost normal metabolism of biogenic amines. It is concluded that while MAO inhibitors may be the primary compound responsible for MAO inhibition, the effects of their metabolites in some cases may also play equally important roles in the regulation of monoamines both in the periphery and the brain.(ABSTRACT TRUNCATED AT 400 WORDS)

Full text

PDF
335

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Birkmayer W., Riederer P., Ambrozi L., Youdim M. B. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet. 1977 Feb 26;1(8009):439–443. doi: 10.1016/s0140-6736(77)91940-7. [DOI] [PubMed] [Google Scholar]
  2. Campbell I. C., Robinson D. S., Lovenberg W., Murphy D. L. The effects of chronic regimens of clorgyline and pargyline on monoamine metabolism in the rat brain. J Neurochem. 1979 Jan;32(1):49–55. doi: 10.1111/j.1471-4159.1979.tb04508.x. [DOI] [PubMed] [Google Scholar]
  3. Eisler T., Teräväinen H., Nelson R., Krebs H., Weise V., Lake C. R., Ebert M. H., Whetzel N., Murphy D. L., Kopin I. J. Deprenyl in Parkinson disease. Neurology. 1981 Jan;31(1):19–23. doi: 10.1212/wnl.31.1.19. [DOI] [PubMed] [Google Scholar]
  4. Elsworth J. D., Glover V., Reynolds G. P., Sandler M., Lees A. J., Phuapradit P., Shaw K. M., Stern G. M., Kumar P. Deprenyl administration in man: a selective monoamine oxidase B inhibitor without the 'cheese effect'. Psychopharmacology (Berl) 1978 Apr 14;57(1):33–38. doi: 10.1007/BF00426954. [DOI] [PubMed] [Google Scholar]
  5. Fowler C. J., Mantle T. J., Tipton K. F. The nature of the inhibition of rat liver monoamine oxidase types A and B by the acetylenic inhibitors clorgyline, l-deprenyl and pargyline. Biochem Pharmacol. 1982 Nov 15;31(22):3555–3561. doi: 10.1016/0006-2952(82)90575-5. [DOI] [PubMed] [Google Scholar]
  6. Glover V., Sandler M., Owen F., Riley G. J. Dopamine is a monoamine oxidase B substrate in man. Nature. 1977 Jan 6;265(5589):80–81. doi: 10.1038/265080a0. [DOI] [PubMed] [Google Scholar]
  7. Glowinski J., Iversen L. L. Regional studies of catecholamines in the rat brain. I. The disposition of [3H]norepinephrine, [3H]dopamine and [3H]dopa in various regions of the brain. J Neurochem. 1966 Aug;13(8):655–669. doi: 10.1111/j.1471-4159.1966.tb09873.x. [DOI] [PubMed] [Google Scholar]
  8. Houslay M. D., Tipton K. F. The nature of the electrophoretically separable multiple forms of rat liver monoamine oxidase. Biochem J. 1973 Sep;135(1):173–186. doi: 10.1042/bj1350173. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Karoum F., Chuang L. W., Eisler T., Calne D. B., Liebowitz M. R., Quitkin F. M., Klein D. F., Wyatt R. J. Metabolism of (-) deprenyl to amphetamine and methamphetamine may be responsible for deprenyl's therapeutic benefit: a biochemical assessment. Neurology. 1982 May;32(5):503–509. doi: 10.1212/wnl.32.5.503. [DOI] [PubMed] [Google Scholar]
  10. Karoum F., Chuang L. W., Wyatt R. J. On the enzymatic hydrolysis of the sulfate conjugate of 3-methoxy-4-hydroxyphenylglycol (MHPG). Biochem Med. 1980 Dec;24(3):314–320. doi: 10.1016/0006-2944(80)90025-3. [DOI] [PubMed] [Google Scholar]
  11. Karoum F., Costa E. Excretion of norepinephrine and dopamine alcoholic metabolites after 6-hydroxydopamine. Biochem Pharmacol. 1974 Feb 1;23(3):533–538. doi: 10.1016/0006-2952(74)90618-2. [DOI] [PubMed] [Google Scholar]
  12. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  13. Levitt P., Pintar J. E., Breakefield X. O. Immunocytochemical demonstration of monoamine oxidase B in brain astrocytes and serotonergic neurons. Proc Natl Acad Sci U S A. 1982 Oct;79(20):6385–6389. doi: 10.1073/pnas.79.20.6385. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Linnoila M., Karoum F., Potter W. Z. Effect of low-dose clorgyline on 24-hour urinary monoamine excretion in patients with rapidly cycling bipolar affective disorder. Arch Gen Psychiatry. 1982 May;39(5):513–516. doi: 10.1001/archpsyc.1982.04290050007002. [DOI] [PubMed] [Google Scholar]
  15. Major L. J., Murphy D. L., Lipper S., Gordon E. Effects of clorgyline and pargyline on deaminated metabolites of norepinephrine, dopamine and serotonin in human cerebrospinal fluid. J Neurochem. 1979 Jan;32(1):229–231. doi: 10.1111/j.1471-4159.1979.tb04533.x. [DOI] [PubMed] [Google Scholar]
  16. Neff N. H., Goridis C. Neuronal monoamine oxidase: specific enzyme types and their rates of formation. Adv Biochem Psychopharmacol. 1972;5:307–323. [PubMed] [Google Scholar]
  17. Reynolds G. P., Elsworth J. D., Blau K., Sandler M., Lees A. J., Stern G. M. Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol. 1978 Dec;6(6):542–544. doi: 10.1111/j.1365-2125.1978.tb00883.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Reynolds G. P., Riederer P., Sandler M., Jellinger K., Seemann D. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J Neural Transm. 1978;43(3-4):271–277. doi: 10.1007/BF01246964. [DOI] [PubMed] [Google Scholar]
  19. Sandler M., Carter S. B., Goodwin B. L., Ruthven C. R., Youdim M. B., Hanington E., Cuthbert M. F., Pare C. M. Multiple forms of monoamine oxidase: some in vivo correlations. Adv Biochem Psychopharmacol. 1974;12(0):3–10. [PubMed] [Google Scholar]
  20. Sandler M., Youdim M. B. Multiple forms of monoamine oxidase: functional significance. Pharmacol Rev. 1972 Jun;24(2):331–348. [PubMed] [Google Scholar]
  21. White H. L., Glassman A. T. Multiple binding sites of human brain and liver monoamine oxidase: substrate specificities, selective inhibitions, and attempts to separate enzyme forms. J Neurochem. 1977 Dec;29(6):987–997. doi: 10.1111/j.1471-4159.1977.tb06502.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES